XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 135 filers reported holding XENON PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 10.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,240,418 | -11.6% | 65,586 | -0.4% | 0.00% | -33.3% |
| Q2 2023 | $2,534,340 | +21.9% | 65,827 | +13.4% | 0.00% | +50.0% |
| Q1 2023 | $2,078,326 | -3.8% | 58,070 | +6.0% | 0.00% | 0.0% |
| Q4 2022 | $2,160,330 | +37.1% | 54,789 | +25.5% | 0.00% | 0.0% |
| Q3 2022 | $1,576,000 | +56.0% | 43,653 | +31.5% | 0.00% | +100.0% |
| Q2 2022 | $1,010,000 | +9.5% | 33,184 | +10.1% | 0.00% | 0.0% |
| Q1 2022 | $922,000 | +18.7% | 30,150 | +21.1% | 0.00% | – |
| Q4 2021 | $777,000 | +171.7% | 24,904 | +33.2% | 0.00% | – |
| Q3 2021 | $286,000 | -17.3% | 18,698 | +0.4% | 0.00% | – |
| Q2 2021 | $346,000 | -19.9% | 18,617 | -22.7% | 0.00% | – |
| Q1 2021 | $432,000 | +52.7% | 24,091 | +30.4% | 0.00% | – |
| Q4 2020 | $283,000 | +87.4% | 18,478 | +35.0% | 0.00% | – |
| Q3 2020 | $151,000 | -12.2% | 13,685 | 0.0% | 0.00% | – |
| Q2 2020 | $172,000 | +20.3% | 13,685 | -5.7% | 0.00% | – |
| Q2 2019 | $143,000 | – | 14,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |